Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients
Status:
Unknown status
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The myeloid-derived suppressor cells (MDSCs) can further trigger cytotoxic T cell apoptosis,
and may shift the macrophages toward M2 subtype, inhibit the Th1 cell, and initiate other
immune suppressive mechanism. The functions of NK cells and regulatory T cells are altered,
resulting in a disturbance of anti-tumor immune function. All these can further create an
environment with a benefit for malignant cell growth and advancement. Astragalus-based
formula may confer its survival advantage in cancer patients through modulating the immune
system and reversing the immunosuppressive microenvironment.
The investigators aim to study the role of Qingshu-Yiqi-Tang in reversing the immune
alterations in patients with advanced stage, non-small cell lung cancer who receive 1st line
doublet chemotherapy of cisplatin plus doxetaxel（or Pemetrexed for adenocarcinoma）and 2nd
line target therapy of erlotinib. The investigators can explore the possible mechanism of the
Astragalus-based formula: Qingshu-Yiqi-Tang in modulating and reversing immunosuppression in
advanced stage, non-small cell lung cancer patients.